

9. (Amended) A composition comprising:

a human phosphorylated prolactin mimic, the mimic in an amount effective to antagonize growth promoting effects of non-phosphorylated human prolactin, the mimic being expressible by SEQ ID NO:1, being mutated at serine 179 and being substantially free of non-phosphorylated human prolactin.

10. The composition as in claim 9 wherein the serine 179 is substituted by an aspartate or glutamate residue.

11. The composition as in claim 9 wherein the serine 179 is substituted by an aspartate residue.

12. The composition as in claim 9 wherein the mimic is admixed with a pharmaceutically suitable carrier.

#### REMARKS

The examiner has made a sequence listing requirement. Accordingly, Applicant has amended the specification so as to conform Figure 1 (which had both the cDNA sequence for human substitution prolactin and also the corresponding substituted amino acid sequence). Appropriate introduction of sequence identifiers and correction of sequence identifiers for primers has been made. Amendment to the claims has also been accomplished.


Applicant has discovered that the description of Fig. 1 was inconsistent with Fig. 1. Fig. 1 illustrates the cDNA sequence of human substitution prolactin where the sequence includes the

signal sequence or pre-piece which is not present in the mature molecule. In the mature molecule, the signal sequence is cleaved off co-translationally. Correction to the Fig. 1 legend in the "Brief Description of the Drawings" is hereby made.

Accordingly, Applicant believes that this application is now in a condition for examination.

Dated: September 30, 1999.

Respectfully submitted,



J. Suzanne Siebert, Reg. No. 28,758  
MAJESTIC, PARSONS, SIEBERT & HSUE P.C.  
Four Embarcadero Center, Suite 1100  
San Francisco, California 94111-4106  
Telephone: (415) 248-5500  
Facsimile: (415) 362-5418

Atty. Docket: 2500.097US2